Tg Therapeutics MACD Death Cross and Bollinger Bands Narrowing on 15min chart

Tg Therapeutics' 15-minute chart has exhibited a MACD Death Cross and Bollinger Bands Narrowing at 09/18/2025 15:45. This indicates that the stock price has the potential to continue falling, with a decreasing magnitude of price fluctuations.

B. Riley Securities has maintained its Buy rating for TG Therapeutics Inc. (TGTX) and raised the price target from $53.00 to $55.00, reflecting a 3.77% increase as of September 17, 2025. The analyst responsible for this update, Mayank Mamtani, suggests that this adjustment aligns with recent market evaluations and strategic company developments. TG Therapeutics continues to be seen favorably within the market, as indicated by the maintained Buy rating.

TG Therapeutics Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Additionally, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials.

According to Wall Street analysts, the average one-year price target for TG Therapeutics Inc. is $42.00, with a high estimate of $55.00 and a low estimate of $11.00. The average target implies an upside of 29.91% from the current price of $32.33. Based on the consensus recommendation from 9 brokerage firms, the average brokerage recommendation is currently 2.2, indicating an "Outperform" status.

B. Riley Securities' updated price target of $55.00 suggests a significant upside potential for TG Therapeutics Inc. However, recent technical indicators, such as the MACD Death Cross and Bollinger Bands Narrowing observed on September 18, 2025, at 15:45, indicate a potential for continued stock price decline with decreasing magnitude of price fluctuations TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].